Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 16 2024 - 4:05PM
Business Wire
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology
company dedicated to developing first-in-class and best-in-class
targeted cancer therapies, today announced the closing of its
underwritten public offering of 10,000,000 shares of its common
stock, including the exercise in full by the underwriters of their
option to purchase an additional 1,500,000 shares, at a price to
the public of $20.00 per share. The gross proceeds to Immunome from
the offering, before deducting underwriting discounts and
commissions and offering expenses, are $230.0 million. All of the
shares in the offering were sold by Immunome.
J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim
Securities acted as joint book-running managers for the offering.
Wedbush PacGrow acted as lead manager for the offering.
The offering was made pursuant to a shelf registration statement
on Form S-3 that was filed with the U.S. Securities and Exchange
Commission (the "SEC") on February 13, 2024 and automatically
became effective upon filing. A preliminary prospectus supplement
and accompanying prospectus relating to the offering were filed
with the SEC and are available for free on the SEC’s website
located at http://www.sec.gov. A final prospectus supplement and
accompanying prospectus relating to the offering were filed with
the SEC and are available for free on the SEC’s website located at
http://www.sec.gov. Copies of the final prospectus supplement and
the accompanying prospectus relating to the offering may be
obtained from: J.P. Morgan Securities LLC, Attention: Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
or by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, 599
Lexington Avenue, New York, NY 10022, by email at
Prospectus_ECM@cowen.com or by telephone at (833) 297-2926; Leerink
Partners LLC, Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or
by email at syndicate@leerink.com; or Guggenheim Securities, LLC
Attention: Equity Syndicate Department, 330 Madison Avenue, New
York, NY 10017 or by telephone at (212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including ADCs, radioligand therapies, immunotherapies,
and small molecules. We believe that pursuing underexplored targets
with appropriate drug modalities leads to transformative therapies.
Our proprietary memory B cell hybridoma technology allows for the
rapid screening and functional characterization of novel antibodies
and targets.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240216984764/en/
Investor Contact: Max Rosett Interim Chief Financial
Officer and EVP, Operations mrosett@immunome.com
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From Apr 2024 to May 2024
Immunome (NASDAQ:IMNM)
Historical Stock Chart
From May 2023 to May 2024